Applied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trial

Phase 3BIOxHEAL™Positive

AI Analysis

Summary

Applied Biologics received central IRB approval to initiate its Phase 3 BIOxHEAL™ clinical trial for diabetic foot ulcers. This approval enables the company to proceed with the late-stage study.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Central IRB approval received

Importance:5/10

Sentiment:

0.60

clinical trialIRB approvaldiabetic foot ulcersPhase 3

Related Companies

$AGTC

Read the original article

Published by GlobeNewswire Clinical Studies on August 5, 2026 11:21 AM

Read Original